Korean Biotechs Relaunching IPOs After Withdrawals Last Year
This article was originally published in PharmAsia News
South Korean companies that withdrew IPO plans late last year due largely to the crowded year-end offering market are now returning. Among them are drug developers Anterogen and Qurient, which successfully relaunched floats in the second-tier Kosdaq market in February.
Register for our free email digests: